QTRX [NASD]
Quanterix Corporation
Index- P/E- EPS (ttm)-1.79 Insider Own7.10% Shs Outstand36.85M Perf Week-10.64%
Market Cap597.56M Forward P/E- EPS next Y-2.38 Insider Trans-1.14% Shs Float34.25M Perf Month1.94%
Income-65.70M PEG- EPS next Q-0.49 Inst Own89.30% Short Float3.94% Perf Quarter-42.48%
Sales112.90M P/S5.29 EPS this Y-50.40% Inst Trans1.82% Short Ratio3.87 Perf Half Y-60.27%
Book/sh11.57 P/B1.45 EPS next Y-6.20% ROA-12.90% Target Price39.50 Perf Year-71.77%
Cash/sh10.52 P/C1.60 EPS next 5Y- ROE-14.70% 52W Range14.58 - 60.95 Perf YTD-60.40%
Dividend- P/FCF- EPS past 5Y-3.30% ROI-13.30% 52W High-72.45% Beta1.53
Dividend %- Quick Ratio12.90 Sales past 5Y44.40% Gross Margin53.10% 52W Low15.16% ATR1.23
Employees460 Current Ratio13.70 Sales Q/Q8.80% Oper. Margin-59.20% RSI (14)46.30 Volatility4.99% 6.96%
OptionableYes Debt/Eq0.00 EPS Q/Q-67.90% Profit Margin-58.20% Rel Volume0.46 Prev Close16.19
ShortableYes LT Debt/Eq0.00 EarningsMay 10 BMO Payout- Avg Volume348.06K Price16.79
Recom1.70 SMA20-1.31% SMA50-10.18% SMA200-50.27% Volume160,045 Change3.71%
Mar-02-22Upgrade Goldman Sell → Neutral $40
Oct-15-21Resumed Cowen Outperform
Jun-04-21Initiated Goldman Sell $53
Jun-30-22 08:00AM  
Jun-09-22 04:30PM  
Jun-06-22 08:36AM  
May-10-22 09:05PM  
08:00AM  
May-09-22 05:45PM  
May-03-22 08:30AM  
Apr-27-22 03:03PM  
Apr-22-22 11:56AM  
08:30AM  
Apr-04-22 04:30PM  
Mar-29-22 04:30PM  
Mar-16-22 06:56AM  
Mar-09-22 04:30PM  
Mar-03-22 04:30PM  
08:12AM  
Mar-01-22 08:55AM  
07:30AM  
07:30AM  
07:30AM  
Feb-28-22 02:29PM  
Feb-24-22 06:40PM  
Feb-23-22 04:30PM  
Feb-09-22 09:00AM  
Feb-07-22 06:43PM  
Jan-26-22 11:30AM  
Jan-13-22 07:30AM  
Jan-06-22 04:30PM  
Dec-21-21 06:38AM  
Dec-16-21 10:00AM  
Dec-15-21 09:57PM  
Nov-18-21 08:43AM  
Nov-17-21 04:15PM  
04:53AM  
Nov-16-21 09:20AM  
Nov-11-21 04:30PM  
Nov-08-21 01:21PM  
Nov-05-21 01:00PM  
Nov-04-21 04:01PM  
06:38AM  
Oct-28-21 04:30PM  
03:05PM  
Oct-26-21 04:54PM  
Oct-12-21 12:22PM  
12:09PM  
07:04AM  
Oct-11-21 04:05PM  
Oct-06-21 06:55AM  
Sep-23-21 10:15AM  
Sep-20-21 08:26AM  
Sep-17-21 12:02PM  
Sep-14-21 07:40AM  
Sep-13-21 05:42PM  
Sep-10-21 05:28PM  
Sep-01-21 10:44AM  
Aug-30-21 11:43AM  
Aug-27-21 04:26PM  
04:10PM  
04:09PM  
11:00AM  
08:58AM  
08:19AM  
07:14AM  
Aug-25-21 07:23AM  
Aug-09-21 04:30PM  
Aug-06-21 07:57AM  
Aug-05-21 08:15PM  
04:18PM  
Jul-28-21 07:04AM  
Jul-27-21 03:03PM  
Jul-21-21 01:53PM  
Jun-28-21 04:08PM  
Jun-19-21 05:53AM  
Jun-11-21 02:31PM  
Jun-07-21 10:13AM  
Jun-02-21 11:02AM  
May-11-21 08:00AM  
May-07-21 09:15AM  
May-05-21 04:01PM  
Apr-28-21 04:30PM  
07:30AM  
Apr-27-21 02:18PM  
Apr-22-21 03:29PM  
Apr-21-21 07:10AM  
Mar-26-21 06:47AM  
Mar-17-21 04:01PM  
Mar-02-21 05:25PM  
04:03PM  
Mar-01-21 10:05AM  
Feb-25-21 06:05PM  
Feb-23-21 11:19AM  
Feb-18-21 11:59AM  
Feb-12-21 02:08PM  
Feb-09-21 08:41AM  
Feb-08-21 03:12PM  
Feb-04-21 07:00AM  
Feb-03-21 04:25PM  
Jan-22-21 03:39PM  
Jan-13-21 08:30AM  
Jan-12-21 03:27AM  
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Toloue MasoudPresident & CEOJun 13Sale15.275,56484,95581,701Jun 14 04:12 PM
Fry John JGeneral Counsel & SecretaryJun 02Sale17.473786,60538,459Jun 03 04:19 PM
HRUSOVSKY E KEVINExecutive ChairmanJun 02Sale17.4771212,441911,209Jun 03 04:19 PM
HRUSOVSKY E KEVINExecutive ChairmanMay 02Sale22.3664914,515911,921May 03 04:34 PM
Fry John JGeneral Counsel & SecretaryMay 02Sale22.364299,59538,837May 03 04:25 PM
HRUSOVSKY E KEVINChairman and CEOApr 01Sale29.7986825,860886,976Apr 05 04:03 PM
Mattoon DawnSr. VP, DiagnosticsApr 01Sale29.792617,77636,876Apr 05 04:02 PM
Fry John JGeneral Counsel & SecretaryApr 01Sale29.7952415,61130,229Apr 05 04:02 PM
Roskey Mark T.SVP, Strategic PartnershipsApr 01Sale29.791715,09522,325Apr 05 04:03 PM
Duffy David C.SVP R&D and CTOMar 23Sale30.003,26697,98054,730Mar 28 05:02 PM
Fry John JGeneral Counsel & SecretaryMar 01Sale31.4637111,67130,753Mar 03 05:00 PM
HRUSOVSKY E KEVINChairman and CEOMar 01Sale31.4658918,530887,844Mar 03 05:01 PM
Roskey Mark T.SVP, Strategic PartnershipsMar 01Sale31.461665,22222,496Mar 03 05:01 PM
Mattoon DawnSr. VP, DiagnosticsMar 01Sale31.462678,39937,137Mar 03 05:00 PM
Fry John JGeneral Counsel & SecretaryFeb 09Sale34.9748116,82031,124Feb 09 05:12 PM
Roskey Mark T.SVP, Strategic PartnershipsFeb 09Sale34.9729210,21122,662Feb 09 05:13 PM
Mattoon DawnSr. VP, DiagnosticsFeb 09Sale34.9731811,12037,404Feb 09 05:12 PM
HRUSOVSKY E KEVINChairman and CEOFeb 09Sale34.971,36447,697888,433Feb 09 05:10 PM
Duffy David C.SVP R&D and CTOFeb 04Sale30.913,266100,95257,996Feb 04 04:01 PM
HRUSOVSKY E KEVINChairman and CEOFeb 02Sale31.4658918,530889,797Feb 04 04:00 PM
Mattoon DawnSr. VP, DiagnosticsFeb 02Sale31.462678,39937,722Feb 04 04:00 PM
Roskey Mark T.SVP, Strategic PartnershipsFeb 02Sale31.461665,22222,954Feb 04 04:01 PM
Fry John JGeneral Counsel & SecretaryFeb 02Sale31.4637111,67131,605Feb 04 04:00 PM
Duffy David C.SVP R&D and CTOJan 31Sale30.003,26697,98061,262Jan 31 04:12 PM
Duffy David C.SVP R&D and CTOJan 03Option Exercise2.5941,246106,70464,528Jan 05 04:04 PM
Mattoon DawnSr. VP, DiagnosticsJan 03Sale41.9135514,87737,989Jan 05 04:06 PM
Roskey Mark T.SVP, Strategic PartnershipsJan 03Sale41.911496,24423,120Jan 05 04:06 PM
Fry John JGeneral Counsel & SecretaryJan 03Sale41.9135214,75131,976Jan 05 04:06 PM
HRUSOVSKY E KEVINChairman and CEOJan 03Sale41.913,715155,683890,386Jan 05 04:06 PM
Duffy David C.SVP R&D and CTODec 29Sale40.711,66767,86423,282Dec 30 04:57 PM
HRUSOVSKY E KEVINChairman and CEODec 01Sale40.293,710149,477894,101Dec 03 04:20 PM
Roskey Mark T.SVP, Strategic PartnershipsDec 01Sale40.291475,92323,269Dec 03 04:19 PM
Fry John JGeneral Counsel & SecretaryDec 01Sale40.2935014,10132,328Dec 03 04:18 PM
Mattoon DawnSr. VP, DiagnosticsDec 01Sale40.2935314,22238,344Dec 03 04:18 PM
Duffy David C.SVP R&D and CTONov 19Sale45.541,66775,91524,949Nov 22 06:18 PM
HRUSOVSKY E KEVINChairman and CEONov 10Sale55.185,000275,897897,811Nov 10 04:06 PM
Mattoon DawnSr. VP, DiagnosticsNov 05Option Exercise19.1210,718204,92847,232Nov 08 04:26 PM
Mattoon DawnSr. VP, DiagnosticsNov 05Sale57.288,535488,85138,697Nov 08 04:26 PM
Mattoon DawnSr. VP, DiagnosticsNov 04Sale57.0015736,514Nov 08 04:26 PM
HRUSOVSKY E KEVINChairman and CEONov 02Sale52.613,505184,385902,811Nov 04 04:19 PM
Roskey Mark T.SVP, Strategic PartnershipsNov 02Sale52.611397,31223,416Nov 04 04:20 PM
Fry John JGeneral Counsel & SecretaryNov 02Sale52.6133117,41232,678Nov 04 04:19 PM
Mattoon DawnSr. VP, DiagnosticsNov 02Sale52.6133317,51836,515Nov 04 04:19 PM
HRUSOVSKY E KEVINChairman and CEOOct 22Sale50.705,000253,520906,316Oct 22 05:48 PM
Duffy David C.SVP R&D and CTOOct 15Sale51.471,66785,80026,616Oct 19 04:00 PM
Roskey Mark T.SVP, Strategic PartnershipsOct 01Sale51.201437,32223,555Oct 05 04:02 PM
Mattoon DawnSr. VP, DiagnosticsOct 01Sale51.2034217,51136,848Oct 05 04:02 PM
Fry John JGeneral Counsel & SecretaryOct 01Sale51.2034017,40833,009Oct 05 04:02 PM
HRUSOVSKY E KEVINChairman and CEOOct 01Sale51.203,594184,015911,316Oct 04 04:02 PM
HRUSOVSKY E KEVINChairman and CEOSep 30Sale49.095,000245,449914,910Oct 04 04:02 PM
Duffy David C.SVP R&D and CTOSep 22Sale47.721,66779,54928,283Oct 04 04:09 PM
HRUSOVSKY E KEVINChairman, President & CEOSep 02Sale49.665,000248,307919,910Sep 03 04:01 PM
HRUSOVSKY E KEVINChairman, President & CEOSep 01Sale49.923,709185,158924,910Sep 03 04:01 PM
Mattoon DawnSr. VP, DiagnosticsSep 01Sale49.9235317,62237,190Sep 03 04:01 PM
Fry John JGeneral Counsel & SecretarySep 01Sale49.9235017,47233,349Sep 03 04:01 PM
Roskey Mark T.SVP, Strategic PartnershipsSep 01Sale49.921477,33823,698Sep 03 04:01 PM
Duffy David C.SVP R&D and CTOAug 20Sale46.131,66776,89929,950Aug 20 04:08 PM
HRUSOVSKY E KEVINChairman, President & CEOAug 16Sale47.335,000236,669928,619Aug 18 04:19 PM
HRUSOVSKY E KEVINChairman, President & CEOAug 03Sale53.793,648196,219933,619Aug 03 09:34 PM
Fry John JGeneral Counsel & SecretaryAug 03Sale53.7934418,50333,699Aug 03 09:32 PM
Mattoon DawnSr. VP, DiagnosticsAug 03Sale53.7934618,61137,543Aug 03 09:31 PM
Roskey Mark T.SVP, Strategic PartnershipsAug 03Sale53.791457,79923,845Aug 03 09:29 PM
HRUSOVSKY E KEVINChairman, President & CEOJul 29Sale54.085,000270,420937,267Jul 30 04:39 PM
Duffy David C.SVP R&D and CTOJul 14Sale57.771,66796,30331,617Jul 14 05:08 PM
HRUSOVSKY E KEVINChairman, President & CEOJul 13Sale57.455,000287,265942,267Jul 14 05:03 PM